Clinical Study

A 2-Year, Multi-Center, Phase II, Open-Label, Fixed-Dose, Randomized Comparative Trial Of Azacitidine, With Or Without Deferasirox In Patients With Hi

Posted Date: May 15, 2019

  • Investigator: Stephen Medlin
  • Specialties:
  • Type of Study: Drug

The purpose of this study is to learn if combining the two drugs, deferasirox (Exjade?) and azacitidine (Vidaza?), is safe and has beneficial effects in people who have Int-2 or High Risk myelodysplastic syndrome (MDS). Deferasirox is an oral medicine (tablet) used to treat iron overload due to bloo

Criteria:

To Be Eligible To Participate, Patients Must Have Been Diagnosed With Higher Risk Myelodysplastic Sy

Keywords:

Mds, Myelodysplastic Synd, Cicl067aus47, Bone Marrow, Cancer

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.